Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

Fluvoxamine is a new antidepressant which potently and specifically inhibits neuronal reuptake of serotonin. In the absence of other major pharmacological effects it appears that its antidepressant activity stems from facilitation of serotoninergic neurotransmission as a result of reuptake inhibition. Studies suggest that fluvoxamine has overall therapeutic efficacy comparable with that of imipramine and clomipramine in depressive illness. It causes fewer anticholinergic-type and cardiovascular side effects than the tricyclic antidepressants but it is associated with a higher incidence of nausea and vomiting. Elderly patients also respond well to fluvoxamine. Studies are now required to compare fluvoxamine with other second generation antidepressants and to establish whether some types of depressive illness respond more readily to fluvoxamine than other agents. Thus, in patients with depressive illness, fluvoxamine offers a suitable alternative to tricyclic antidepressants and may be especially valuable in patients with concomitant cardiovascular disease, and those unresponsive to or unable to tolerate tricyclic antidepressants.

[1]  H. Hall,et al.  Acute effects of atypical antidepressants on various receptors in the rat brain. , 2009, Acta pharmacologica et toxicologica.

[2]  E. Paykel,et al.  A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients. , 1984, Journal of affective disorders.

[3]  E. Richelson,et al.  Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. , 1984, The Journal of pharmacology and experimental therapeutics.

[4]  E. Paykel,et al.  FLUVOXAMINE: ANTIDEPRESSANT EFFECTS CONFIRMED IN A PLACEBO-CONTROLLED INTERNATIONAL STUDY , 1984 .

[5]  J. Munro,et al.  A PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF FLUVOXAMINE MALEATE IN THE OBESE , 1984 .

[6]  J. Scuvée-Moreau,et al.  THE EFFECTS OF VARIOUS ANTIDEPRESSANTS ON THE SPONTANEOUS FIRING RATES OF NORADHENERGIC AND SEROTONERGIC NEURONS , 1984 .

[7]  B. Saletu,et al.  Pharmaco-EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine. , 1983, British journal of clinical pharmacology.

[8]  W. Wouters,et al.  Acute cardiac effects of fluvoxamine and other antidepressants in conscious rabbits. , 1983, Archives internationales de pharmacodynamie et de therapie.

[9]  A. Coppen,et al.  Drug plasma levels and platelet 5-HT uptake inhibition during long-term treatment with fluvoxamine or lithium in patients with affective disorders. , 1983, British journal of clinical pharmacology.

[10]  W. Wilson,et al.  A double-blind placebo-controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers. , 1983, British journal of clinical pharmacology.

[11]  R. Shrivastava,et al.  A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. , 1983, British journal of clinical pharmacology.

[12]  D. Cocchi,et al.  Neuroendocrine studies with fluvoxamine: animal data. , 1983, British journal of clinical pharmacology.

[13]  P. Dick,et al.  A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine. , 1983, British journal of clinical pharmacology.

[14]  J. C. Roos,et al.  Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine. , 1983, British journal of clinical pharmacology.

[15]  V. Claassen.  Review of the animal pharmacology and pharmacokinetics of fluvoxamine. , 1983, British journal of clinical pharmacology.

[16]  C. Mertens,et al.  Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing. , 1983, British journal of clinical pharmacology.

[17]  B. Block,et al.  Fluvoxamine maleate, a serotonergic antidepressant; A comparison with chlorimipramine , 1982, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[18]  F. Petraglia,et al.  Stimulation of beta-endorphin and beta-lipotropin release from the anterior but not the neurointermediate pituitary lobe in the rat after acute administration of serotonin-acting drugs. , 1982, Life sciences.

[19]  D. Doogan,et al.  A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers. , 1982, British journal of clinical pharmacology.

[20]  R. Veith,et al.  Depression in the Elderly: Pharmacologic Considerations in Treatment , 1982, Journal of the American Geriatrics Society.

[21]  J. Himmelhoch,et al.  The dilemma of depression in the elderly. , 1982, The Journal of clinical psychiatry.

[22]  D. Doogan,et al.  Fluvoxamine and chlorimipramine in endogenous depression. , 1982, Journal of affective disorders.

[23]  G. Skuza,et al.  Fluvoxamine, a new antidepressant drug, fails to show antiserotonin activity. , 1982, European journal of pharmacology.

[24]  H. M. Praag,et al.  Fluvoxamine and clomipramine in depressed patients A DOUBLE‐BLIND CLINICAL STUDY , 1981, Acta psychiatrica Scandinavica.

[25]  Wong Dt,et al.  Subsensitivity of serotonin receptors after long-term treatment of rats with fluoxetine. , 1981 .

[26]  G. Hertting,et al.  FLUVOXAMINE, A SPECIFIC 5‐HYDROXYTRYPTAMINE UPTAKE INHIBITOR , 1977, British journal of pharmacology.

[27]  J. Schnitker,et al.  The cardiotropic effect of antidepressants: a comparison with fluvoxamine , 1986 .

[28]  H. Emrich,et al.  Sleep-EEG variables as course criteria and predictors of antidepressant therapy with fluvoxamine/oxaprotiline , 1986 .

[29]  B. Goldstein,et al.  A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. , 1985, The Journal of clinical psychiatry.

[30]  S. Chakravarti,et al.  The tolerance and antidepressive activity of fluvoxamine as a single dose compared to a twice daily dose. , 1985, Current medical research and opinion.

[31]  T. Crook.  Geriatric psychopathology: An overview of the ailments and current therapies , 1985 .

[32]  W. Wilson,et al.  A double‐blind clinical trial of fluvoxamine and imipramine in patients with primary depression , 1984, Psychopharmacology bulletin.

[33]  P. Scherpenisse,et al.  Fluvoxamine: metabolic fate in animals. , 1984, Drug metabolism and disposition: the biological fate of chemicals.

[34]  D. Bradford,et al.  Comparison of the (pro)convulsive properties of fluvoxamine and clovoxamine with eight other antidepressants in an animal model. , 1984, Neuropsychobiology.

[35]  R. L. Singhal,et al.  Fluvoxamine influences serotonergic system in the brain: neurochemical evidence. , 1983, Neuropsychobiology.

[36]  F. Sulser.  Mode of action of antidepressant drugs. , 1983, The Journal of clinical psychiatry.

[37]  H. Denber,et al.  Long-term study of fluvoxamine: a new rapid-acting antidepressant. , 1982, International pharmacopsychiatry.

[38]  W. Haefely,et al.  Selective suppression of rapid eye movement sleep (REMS) in cats by typical and atypical antidepressants. , 1982, Advances in biochemical psychopharmacology.

[39]  P. Dick,et al.  Antidepressants and serotonin neurons of the raphe. , 1981, Neuropsychobiology.

[40]  B. Blackwell.  Adverse effects of antidepressant drugs. Part 1: monoamine oxidase inhibitors and tricyclics. , 1981, Drugs.

[41]  T. Itil,et al.  Fluvoxamine (DU-23,000), a new antidepressant. Quantitative pharmaco-electroencephalography and pilot clinical trials , 1977 .

[42]  J. Feighner,et al.  Diagnostic criteria for use in psychiatric research. , 1972, Archives of general psychiatry.